Targeting Beta-Amyloid and Tau in Alzheimer's Research
A
Alfred Sandrock, Chief Medical Officer at Biogen, during the Milken Institute panel discussion.
Mental HealthMedical
Story of claim
Alfred Sandrock highlights the current focus of most companies on targeting beta-amyloid and tau proteins for Alzheimer's treatment. These proteins are toxic when misfolded, damaging neurons.
- Goal: Develop treatments that target beta-amyloid and tau pathways to combat Alzheimer's disease.
- Proof: Targeting beta-amyloid and tau can potentially reduce neuronal damage caused by protein build-up, as companies are in phase 3 clinical trials.
- Nuances:
- Beta-amyloid and tau are toxic when misfolded
- Clinical trials targeting these pathways are in phase 3
- Impact on Life: Potential to improve life quality for Alzheimer's patients through reduced neuronal damage, possibly slowing disease progression.
Investments
- Price: Not directly stated, but high due to clinical trials and research.
- Time: Several years for clinical trials and drug development.
- Effort: High effort in R&D and maintaining long-term trials.
Risks
Clinical trials may not yield successful treatment outcomes; potential side effects of new treatments are unknown.
Alternatives
- Lifestyle changes: focusing on diet, exercise, and mental health to manage symptoms
- Existing Alzheimer's medications for symptom management
Get Started 🚀
- Stay informed about clinical trial results and new research
- Consider participating in clinical trials if eligible
- Consult healthcare providers about emerging treatments
Brogevity AI can make mistakes. Check important info.